AKAkebia Therapeutics, Inc. AKBA · NASDAQ
$0.67 -3.67% (-$0.03)
- Market cap
- $186.6M
- Enterprise value
- $85.0M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 0.9x
- P/FCF
- 4.6x
- EV/EBITDA
- -
- ROIC
- -7.5%
- Gross margin
- 79.5%
- Net margin
- -13.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.24
- Free float
- 97.3%
About the company
Akebia Therapeutics, Inc. (AKBA) is an American biotechnology company focused on developing medications for the treatment of kidney-related diseases and other medical conditions. The company is dedicated to discovering and advancing novel therapeutic approaches, including drugs for anemia associated with chronic kidney disease. Akebia Therapeutics aims to innovate and provide new treatment options for patients with serious health issues. The biotechnology industry can be influenced by regulatory approval processes and developmental milestones. Akebia Therapeutics, Inc. (AKBA) shares could be an intriguing choice for investors interested in the healthcare sector and biotechnology.
Sector
Healthcare
Industry
Biotechnology
CEO
John Butler
Employees
194
Headquarters
Waltham
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number